---
url: 'https://qubit.capital/blog/uk-seed-weekly-funding-roundup-week-4-march-2026'
title: 'UK Seed Weekly Funding Roundup (Mar 16-23, 2026): $11.1M Raised Across 2 Deals'
author:
  name: Vaibhav Totuka
  url: 'https://qubit.capital/blog/author/vaibhav-totuka'
date: '2026-03-23T08:12:43+05:30'
modified: '2026-03-27T16:44:16+05:30'
type: post
summary: Two UK seed deals raised $11.1M this week. Ternary Therapeutics closed $4.5M for molecular glue drugs. VerbaFlo raised $6.6M for AI real estate comms.
categories:
  - Weekly Funding Roundup
image: 'https://qubit.capital/wp-content/uploads/2026/03/featured-uk-seed-64551.webp'
published: true
---

# UK Seed Weekly Funding Roundup (Mar 16-23, 2026): $11.1M Raised Across 2 Deals

UK seed-stage startups raised $11.1M across two deals this week, with capital flowing into biotech drug design and AI-powered property tech. Both rounds backed founders tackling large, entrenched markets with technical approaches that go beyond surface-level automation.

These seed rounds land alongside a much busier week for later-stage UK companies. Series A deals totalled $61M across three rounds, while Series B and beyond pulled in $57M from two deals. The spread suggests a healthy pipeline: early bets are being placed in parallel with scale-up capital finding its targets.
 

Weekly Funding Roundup
MAR 16-23, 2026

$8.9M
TOTAL RAISED

2DEALS CLOSED
100%SEED
$4.4MAVG DEAL SIZE
UKTOP REGION

BY STAGE
Seed$8.9M100%

BY SECTOR
VerbaFloSaaS / PropTech$5.3M
Ternary TherapeuticsHealthtech / Biotech$3.6M

        
            
            
                
                    
                        
                            
                                
                                    Table of Contents                                
                                
                                                                    
                            
                            
                                
                                        

      - 
        [1. Ternary Therapeutics Raises $4.5M For Molecular Glue Drug Design](#1-ternary-therapeutics-raises-$4-5m-for-molecular-glue-drug-design)
        

          
            [Deal Overview](#deal-overview)
          

          - 
            [Investor Profile](#investor-profile)
          

          - 
            [Company and Leadership](#company-and-leadership)
          

          - 
            [Problem and Opportunity](#problem-and-opportunity)
          

          - 
            [Product and Technology](#product-and-technology)
          

          - 
            [Use of Proceeds and Vision](#use-of-proceeds-and-vision)
          

          - 
            [Market Context](#market-context)
          

        

      
      - 
        [2. VerbaFlo Raises $6.6M For AI Real Estate Communications](#2-verbaflo-raises-$6-6m-for-ai-real-estate-communications)
        

          
            [Deal Overview](#deal-overview-1)
          

          - 
            [Investor Profile](#investor-profile-1)
          

          - 
            [Company and Leadership](#company-and-leadership-1)
          

          - 
            [Problem and Opportunity](#problem-and-opportunity-1)
          

          - 
            [Product and Technology](#product-and-technology-1)
          

          - 
            [Use of Proceeds and Vision](#use-of-proceeds-and-vision-1)
          

          - 
            [Market Context](#market-context-1)
          

        

      
      - 
        [Lessons For Founders](#lessons-for-founders)
      

    

                                
                            
                        
                    
                    
                        
                    
                
            

    
## 1. Ternary Therapeutics Raises $4.5M For Molecular Glue Drug Design
 
### Deal Overview

- **Stage:** Seed

- **Sector:** Healthtech / Biotech

- **Geography:** United Kingdom

- **Round size:** £3.6M (~$4.5M)

 
### Investor Profile

Specific investors in this round have not been publicly disclosed. The £3.6M seed signals early conviction in a technically demanding area of drug discovery where capital requirements grow quickly once candidates move toward preclinical validation.
 
### Company and Leadership

[Ternary Therapeutics](https://www.ternarytherapeutics.com) is building at the intersection of AI, physics, and drug design. The company is focused on molecular glue degraders, a class of small molecules that force two proteins together to trigger the destruction of a disease-causing target. Leadership details remain limited at this stage, though the technical ambition of the platform points to deep domain expertise in computational chemistry and structural biology.
 
### Problem and Opportunity

Most proteins linked to disease can’t be reached by traditional drugs. Roughly 85% of the human proteome is considered “undruggable” by conventional small molecules or antibodies. Molecular glues offer a workaround: instead of blocking a protein directly, they hijack the body’s own protein disposal system to eliminate it. The challenge is that designing these molecules has relied heavily on serendipity. Ternary wants to make the process predictable.
 
### Product and Technology

The company’s platform combines physics-based modelling with AI to design molecular glue compounds from first principles. Rather than screening millions of compounds hoping for a hit, Ternary aims to computationally predict which molecular structures will form the right three-way complex between a target protein, a glue molecule, and the body’s degradation machinery. This approach could dramatically compress discovery timelines for targeted protein degradation therapies.
 
### Use of Proceeds and Vision

Funds will go toward advancing the computational platform and moving initial drug candidates toward preclinical milestones. The long-term bet is that physics-driven design can unlock molecular glue therapies against targets that have resisted decades of conventional drug discovery.
 
### Market Context

The targeted protein degradation market is projected to grow rapidly, driven by the success of early molecular glue drugs like thalidomide derivatives in blood cancers. Big pharma is paying attention: Novartis, Bristol Myers Squibb, and others have made multi-billion-dollar bets in this space. The computational approach Ternary is pursuing puts it in a growing cohort of AI-first biotech startups, though few are focused on molecular glue design from a physics-based angle.
 
## 2. VerbaFlo Raises $6.6M For AI Real Estate Communications
 
### Deal Overview

- **Stage:** Seed

- **Sector:** SaaS / PropTech

- **Geography:** United Kingdom

- **Round size:** £5.26M (~$6.6M)

 
### Investor Profile

Investor names for VerbaFlo’s seed round have not been publicly disclosed. The round size, £5.26M, is substantial for a UK seed and suggests confidence in a product that’s already demonstrating traction or clear demand signals from property management firms.
 
### Company and Leadership

[VerbaFlo](https://www.verbaflo.com) is a UK-based startup automating communications workflows for the real estate sector. The founding team’s background has not been widely profiled, but the product focus on a notoriously communication-heavy industry suggests firsthand experience with the pain points of property management.
 
### Problem and Opportunity

Property management generates a staggering volume of repetitive communication: tenant queries, maintenance requests, lease renewals, compliance notices, viewings coordination. Most of this still runs through email chains, phone calls, and disconnected CRMs. For agencies managing hundreds or thousands of units, this creates a bottleneck that doesn’t scale with headcount alone.
 
### Product and Technology

VerbaFlo’s AI platform automates tenant and stakeholder communications across the property lifecycle. The system handles engagement workflows, from initial enquiries through ongoing property management, reducing the manual load on agents and property managers. By sitting across multiple communication channels, it aims to create a single layer that replaces fragmented tools and manual follow-ups.
 
### Use of Proceeds and Vision

The seed capital will likely fund product development, early customer acquisition among UK letting agents and property management firms, and expansion of the AI capabilities to cover more of the communication chain. The vision is to become the default communications layer for real estate operations, starting with the UK market.
 
### Market Context

The UK has over 2 million privately rented homes and thousands of letting agencies, many still running on outdated workflows. PropTech investment has picked up across Europe, though most capital has gone toward transaction platforms and marketplace models. Vertical SaaS tools for property operations remain underbuilt. Competitors include legacy CRMs adapted for property use and newer entrants like Fixflo and Arthur, but few are tackling the communications layer with AI-first automation.
 
## Lessons For Founders

- **Deep technical moats still attract seed capital.** Ternary’s physics-plus-AI approach to drug design shows that investors will back hard science at seed stage when the market opportunity is large enough. If your differentiation requires years of R&D to replicate, that’s a feature, not a bug.

- **Vertical AI in boring industries works.** VerbaFlo isn’t chasing a flashy market. Property communications is tedious, repetitive, and high-volume, which makes it a perfect fit for AI automation. Look for sectors where the work is painful but the incumbents haven’t modernised.

- **UK seed rounds are getting larger.** A £5.26M seed for a PropTech startup signals that UK investors are willing to write bigger early cheques when the category and timing align. Founders shouldn’t anchor to outdated expectations about round sizes.

- **Undisclosed investors don’t mean weak rounds.** Neither deal named specific backers, but both raised meaningful capital. Early-stage investors sometimes prefer to stay quiet. Don’t mistake a lack of press coverage for a lack of conviction.

